SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-006352
Filing Date
2022-03-09
Accepted
2022-03-09 08:00:40
Documents
15
Period of Report
2022-03-09
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 36956
2 ex99-1.htm EX-99.1 63267
3 form8-k_001.jpg GRAPHIC 7883
4 ex99-1_001.jpg GRAPHIC 7986
  Complete submission text file 0001493152-22-006352.txt   314535

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE lpcn-20220309.xsd EX-101.SCH 3033
6 XBRL LABEL FILE lpcn-20220309_lab.xml EX-101.LAB 34476
7 XBRL PRESENTATION FILE lpcn-20220309_pre.xml EX-101.PRE 22595
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3603
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

IRS No.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36357 | Film No.: 22723951
SIC: 2834 Pharmaceutical Preparations